Experts Warn Concentrated Kratom Products Could Fuel Next Addiction Crisis

Why it matters

As kratom transitions from fringe supplement to mainstream gas station product, clinicians and public health experts are raising alarms about addiction potential — especially with the rise of ultra-concentrated 7-OH formulations that bear little resemblance to traditional kratom leaf.

The big picture

Kratom is a plant-based substance derived from the Mitragyna speciosa tree native to Southeast Asia. At low doses it acts as a stimulant; at higher doses it produces opioid-like effects by binding to the same brain receptors as morphine. While natural kratom leaf has been used for centuries in traditional contexts, modern concentrated extracts — particularly 7-hydroxymitragynine products — have a dramatically different pharmacological profile that addiction experts say is driving rising hospitalizations and dependence cases across the U.S.

Key findings

• Kratom acts as a stimulant at low doses and produces opioid-like effects at higher doses, binding to the same brain receptors as morphine
• Addiction specialists report rising cases of kratom dependence, increasingly linked to concentrated extract products
• Hospitalizations involving kratom-related adverse events have increased, according to U.S. poison control data
• Multiple U.S. states have moved to restrict or ban kratom amid growing public health concerns
• The FDA does not approve kratom for any medical use and has issued repeated public warnings

What they say

Medindia Medical Review Team: "Rising hospitalizations, concerns about dependence, and the emergence of highly concentrated kratom products have sparked warnings that the substance could contribute to a new addiction crisis."

Bottom line

The public health risk from kratom is increasingly tied not to traditional leaf products but to concentrated high-potency extracts — and regulators and clinicians are struggling to keep up.